ADAM10 as a biomarker for Alzheimer's disease: A systematic review

Almeida, M.P. Oliveira Monteiro e Pereira de; Pedroso, Renata Valle; Grigoli, Marina Mantellatto; Silva, Tarcília; Manzine, Patrícia Regina; Cominetti, Márcia Regina

doi:10.1016/j.neurol.2023.04.002

Cited by 6 publications

(2 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It could be speculated that the increase in the density of the active form of ADAM-10 in the striatum is related to a compensatory mechanism to slow the progression of the disease. This contention might be supported by the observation that ADAM-10 levels in plasma from AD subjects are increased [37]. However, the existence of contradictory results on ADAM-10 levels in the CSF of AD patients [37] underscores the need for a further detailed interpretation of the increased activity of ADAM-10 within the brain of AD, for example, compared to PD.…”

Section: Discussionmentioning

confidence: 99%

“…This contention might be supported by the observation that ADAM-10 levels in plasma from AD subjects are increased [37]. However, the existence of contradictory results on ADAM-10 levels in the CSF of AD patients [37] underscores the need for a further detailed interpretation of the increased activity of ADAM-10 within the brain of AD, for example, compared to PD.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

GPR37 Processing and Density in Neurodegeneration: A Potential Marker for Parkinson’s Disease Progression Rate

Argerich,

Garma,

López-Cano

et al. 2024

Preprint

View full text Add to dashboard Cite

Background The orphan G protein-coupled receptor 37 (GPR37), widely associated with Parkinson's disease (PD), undergoes proteolytic processing under physiological conditions. The N-terminus domain is proteolyzed by a disintegrin and metalloproteinase 10 (ADAM-10), which generates various membrane receptor forms and ectodoamin shedding (ecto-GPR37) in the extracellular environment. Methods We investigated the processing and density of GPR37 in several neurodegenerative conditions, including Lewy body disease (LBD), multiple system atrophy (MSA), corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), and Alzheimer's disease (AD). The presence of ecto-GPR37 peptides in the cerebrospinal fluid (CSF) of PD, MSA, CBD and PSP patients was assessed through an in-house nanoluciferase-based immunoassay. Results This study identified increased receptor processing in early-stage LBD within the PFC andstriatum, key brain areas in neurodegeneration. In MSA only the 52 kDa form of GPR37 appeared in the striatum. This form was also elevated in the PFC and striatum of AD necropsies. On the contrary, GPR37 processing remained unchanged in the brains of CBD and PSP patients. Furthermore, while CSF ecto-GPR37 increased in PD patients, its levels remained unchanged in MSA, CBD, and PSP subjects. Importantly, patients with PD with rapid progression of the disease did not have elevated ecto-GPR37 in the CSF, while those with slow progression showed a significant increase, suggesting a possible prognostic use of ecto-GPR37 in PD. Conclusions This research underscores the distinctiveprocessing and density patterns of GPR37 in neurodegenerative diseases, providing crucial insights into its potential role as a predictor of PD progression rates.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%